As a result, the PD-1/PD-L1 checkpoint therapeutic blockade using monoclonal antibodies against PD-1 or PD-L1 blocks the PD-1/PD-L1 interaction and activates T cell-mediated cancer cell death. The gene discussed is CD274; the disease is cancer.